Perryman Financial Advisory Inc. AD Acquires New Stake in Merck & Co., Inc. $MRK

Perryman Financial Advisory Inc. AD acquired a new stake in Merck & Co., Inc. (NYSE:MRK) during the 4th quarter, according to its most recent disclosure with the SEC. The fund acquired 56,068 shares of the company’s stock, valued at approximately $5,902,000.

Other institutional investors have also added to or reduced their stakes in the company. Kingdom Financial Group LLC. bought a new stake in Merck & Co., Inc. in the 4th quarter valued at $25,000. United Financial Planning Group LLC bought a new stake in Merck & Co., Inc. during the 3rd quarter worth about $31,000. High Note Wealth LLC lifted its position in Merck & Co., Inc. by 58.9% during the 4th quarter. High Note Wealth LLC now owns 294 shares of the company’s stock worth $31,000 after buying an additional 109 shares in the last quarter. IFC & Insurance Marketing Inc. bought a new stake in Merck & Co., Inc. during the 4th quarter worth about $31,000. Finally, Gilpin Wealth Management LLC bought a new stake in Merck & Co., Inc. during the 4th quarter worth about $32,000. 76.07% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

MRK has been the topic of several analyst reports. Royal Bank Of Canada reissued an “outperform” rating and set a $142.00 price target on shares of Merck & Co., Inc. in a research report on Monday, March 30th. JPMorgan Chase & Co. boosted their price target on shares of Merck & Co., Inc. from $125.00 to $135.00 and gave the stock an “overweight” rating in a research report on Monday, April 6th. UBS Group boosted their price target on shares of Merck & Co., Inc. from $130.00 to $145.00 and gave the stock a “buy” rating in a research report on Monday, April 13th. Weiss Ratings cut shares of Merck & Co., Inc. from a “hold (c+)” rating to a “hold (c)” rating in a research report on Friday, May 15th. Finally, Wells Fargo & Company cut their price target on shares of Merck & Co., Inc. from $150.00 to $145.00 and set an “overweight” rating on the stock in a research report on Friday, May 1st. One equities research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and seven have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Merck & Co., Inc. currently has a consensus rating of “Moderate Buy” and an average price target of $128.18.

Trending Headlines about Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck Animal Health announced a definitive agreement to acquire TARGAN, a poultry biodevice company, which could strengthen Merck’s animal health division and broaden its technology-driven growth opportunities. Merck Animal Health to Acquire TARGAN
• Positive Sentiment: Merck saw unusually heavy call option buying, with traders purchasing 170,441 calls, a sharp jump versus normal volume that often signals bullish expectations from sophisticated investors.
• Positive Sentiment: Wells Fargo reiterated a buy rating on Merck, while another article highlighted that Wall Street’s overall bullish view continues to keep MRK on investors’ radar.
• Neutral Sentiment: Merck has also been featured in broader market commentary and “most searched” lists, suggesting rising attention rather than a new fundamental catalyst.
• Neutral Sentiment: One article noted Merck’s recent trading uptick but said it lagged the broader market, indicating modest price strength rather than a major breakout. Merck (MRK) Rises Yet Lags Behind Market: Some Facts Worth Knowing

Merck & Co., Inc. Stock Up 0.0%

Merck & Co., Inc. stock opened at $119.05 on Monday. The firm has a market capitalization of $294.04 billion, a PE ratio of 33.54, a P/E/G ratio of 2.68 and a beta of 0.21. The company’s 50-day moving average is $116.55 and its 200-day moving average is $113.32. Merck & Co., Inc. has a fifty-two week low of $76.66 and a fifty-two week high of $125.14. The company has a debt-to-equity ratio of 1.02, a current ratio of 1.30 and a quick ratio of 1.06.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings data on Thursday, April 30th. The company reported ($1.28) earnings per share for the quarter, topping the consensus estimate of ($1.47) by $0.19. The company had revenue of $16.29 billion for the quarter, compared to analyst estimates of $15.85 billion. Merck & Co., Inc. had a net margin of 13.59% and a return on equity of 27.55%. Merck & Co., Inc.’s revenue for the quarter was up 4.9% compared to the same quarter last year. During the same period in the previous year, the business earned $2.22 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. Sell-side analysts anticipate that Merck & Co., Inc. will post 5.17 earnings per share for the current year.

Merck & Co., Inc. Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 8th. Stockholders of record on Monday, June 15th will be paid a dividend of $0.85 per share. The ex-dividend date is Monday, June 15th. This represents a $3.40 annualized dividend and a dividend yield of 2.9%. Merck & Co., Inc.’s payout ratio is currently 95.77%.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.